Bookmark and Share

Lipid-lowering intensification and low-density lipoprotein cholesterol achievement from hospital admission to 1-year follow-up after an acute coronary syndrome event: results from the Medications ApplIed aNd SusTAINed Over Time (MAINTAIN) registry

Melloni C, Shah BR, Ou FS, Roe MT, Smith SC Jr, Pollack CV Jr, Ohman M, Gibler WB, Peterson ED, Alexander KP.
Am Heart J 2010;160:1121-1129

BACKGROUND: Current American College of Cardiology/American Heart Association guidelines recommend initiation or intensification of statin therapy to achieve low-density lipoprotein cholesterol (LDL-C) goals after an acute coronary syndrome (ACS), yet little is known about the actual practice of intensifying lipid-lowering (LL) therapy and LDL-C achievement from hospital admission to 1-year follow-up.
METHODS: The MAINTAIN registry enrolled ACS patients from January 2006 through September 2007, collecting data on statin formulation, dose, and lipid profiles at both baseline and 12 months. Statin intensity (estimated LDL-C lowering) was categorized by formulation and dose as either moderate (<40%) or intensive (=40%). In-hospital LL intensification is described and LDL goal attainment is reported for patients with complete baseline and 12-month lipid panels.
RESULTS: Of the 788 patients without contraindications to LL, 40% were on LL therapy before admission, and 89% at discharge. Among patients on LL therapy with LDL-C>100 mg/dL at admission, only 37% (n=38) had their LL therapy intensified. Among 382 patients with 12 months of data, 89% (n=341) were discharged on a statin. Of these, 89% were still on a statin at 12-month follow-up. A LDL-C goal of =100 mg/dL was achieved in 71% of patients, but the optional LDL-C goal=70 mg/dL was achieved in only 31%.
CONCLUSIONS: Most high-risk ACS patients are prescribed statin therapy at hospital discharge and remain on therapy at 12-month follow-up. Despite this, the LDL-C goal of =70 mg/dL is achieved in a small minority. There is substantial opportunity to intensify LL therapy after ACS to achieve guideline LDL-C goals and prevent future morbidity and mortality.


Am Heart J 2010;160:1121-1129



Area Soci


33° Congresso Nazionale

33° Congresso Nazionale

Roma, 24-26 novembre 2019
Save the date

[continua a leggere]

Spring Meeting Gruppi Giovani SIIA, SIMI, SISA 2019

28 febbraio - 2 marzo 2019

[continua a leggere]

Congresso Regionale SISA Sezione Adriatica

Chieti, 15 Dicembre 2018

[continua a leggere]

EAS Advanced Course in Rare Lipid Disease

Cinisello B.mo (Mi), 19 Ottobre 2018

[continua a leggere]

Congresso Regionale SISA Piemonte-Liguria-Val d'Aosta

Pollenzo, Bra (CN), 13 Ottobre 2018

[continua a leggere]

Congresso Regionale SISA Sezione Campania

Napoli, 11 Ottobre 2018

[continua a leggere]

Congresso Regionale SISA Sezione Lombardia

Milano, 4-6 Ottobre 2018
Assegnati i premi

[continua a leggere]

Giornale Italiano Arteriosclerosi

Rivista in lingua italiana
riservata ai Soci S.I.S.A.
Ultimo numero:
Anno 9 • N.4/2018

[continua a leggere]

Rivista NMCD

Nutrition, Metabolism and Cardiovascular Diseases

Istruzioni per l'accesso online

IF 2017: 3.318


Per essere informati sulle novità di S.I.S.A. iscrivetevi alla nostra newsletter inserendo
il vostro indirizzo di posta elettronica

Progetto LIPIGEN

Nuovo sito dedicato al Progetto LIPIGEN


Progetto LIPIGEN - Vecchio portale
E' necessario essere loggati come utente
Lipigen per poter accedere alla pagina

PROject Statin Intolerance SISA


PROSISA – PROject Statin Intolerance SISA
E' necessario essere loggati come utente
PROSISA per poter accedere alla pagina

GILA - Lipoprotein Aferesi


Gruppo Interdisciplinare Lipoprotein Aferesi
(Accesso Gruppo GILA-Lipoprotein Aferesi)

E' necessario essere loggati come utente del Gruppo GILA per poter accedere


Gruppo Interdisciplinare Lipoprotein Aferesi
(Documentazione ad accesso libero)

Pagina informativa per medici e pazienti